A
Angion Biomedica
Clinical stage organ restoration biopharmaceutical company focused on renal disease
About Angion Biomedica
Angion Biomedica Corp is a late-stage clinical company focused on developing small molecules aimed at treating acute organ injury and chronic fibrosis. The company's lead product, ANG-3777, is designed to activate the HGF c-Met pathway, a critical mechanism in organ repair. Angion's primary market includes patients suffering from acute kidney injury related to kidney transplantation and acute lung injury associated with COVID-19 pneumonia. The business model revolves around advancing its clinical trials to achieve regulatory approval, thereby enabling commercialization and partnerships with healthcare providers and pharmaceutical companies. Revenue is generated through the development and potential future sales of its therapeutic products, as well as possible licensing agreements. Angion operates in the biopharmaceutical sector, targeting unmet medical needs in organ injury and fibrosis.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 1998
- Headquarters
- Hempstead, United States
- Employees
- 18
- Open positions
- None listed
- Dealroom signal
- 26.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Surgery, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
- Investment activity
- 1 company, latest Jan 2023
- Capital deployed
- —
- Preferred round
- POST IPO DEBT
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jan 2023 | $0 | — | Elicio Therapeutics | ↗ |
| IPO✓Exit | Feb 2021 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Angion Biomedica is 4.7K monthly website visits, up 147.4% over the last three months. Angion Biomedica's team declined 14.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Small Business Innovation Research
US National Science Foundation
US Department of War
Other known investors2 additional known investors
Elicio Therapeutics
Formic Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Angion Biomedica on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Angion Biomedica’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.